J Clin Pharm Ther. 2021 Jul 20; doi: 10.1111/jcpt.13496. Epub 2021 Jul 20.

Ursodeoxycholic acid markedly promotes the absorption of microemulsion-formulated cyclosporine A: A case report.

Journal of clinical pharmacy and therapeutics

Hidemi Takeshima, Naoki Yoshikawa, Keiichi Akizuki, Tomonori Hidaka, Kazuya Shimoda, Ryuji Ikeda

PMID: 34288009 DOI: 10.1111/jcpt.13496

Abstract

WHAT IS KNOWN AND OBJECTIVE: Cyclosporine A (CyA) causes intrahepatic biliary stasis via inhibition of bile acid excretion through the bile salt export pump. We report a case of a patient in whom ursodeoxycholic acid (UDCA) markedly promoted the absorption of microemulsion-formulated CyA.

CASE SUMMARY: The patient was a 22-year-old Japanese man diagnosed with stage 3 aplastic anaemia. He was treated with CyA, and 2 h post-dose (C2) was increased by UDCA.

WHAT IS NEW AND CONCLUSION: A remarkable interaction was observed between CyA and UDCA. This is a valuable finding for improving the treatment strategies for haematological disorders.

© 2021 John Wiley & Sons Ltd.

Keywords: bile salt export pump; cyclosporine A; drug-drug interaction; therapeutic drug monitoring; ursodeoxycholic acid

References

1. Colombo D, Ammirati E. Cyclosporine in transplantation-A history of converging timelines. J Biol Regul Homeost Agents. 2011;25:493-504. - PubMed
2. Han K, Pillai VC, Venkataramanan R. Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J. 2013;15:901-912. https://doi.org/10.1208/s12248-013-9500-8 - PubMed
3. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118:485-500. https://doi.org/10.1093/toxsci/kfq269 - PubMed
4. International Transporter Consortium, Giacomini KM, Huang S-M, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236. https://doi.org/10.1038/nrd3028 - PubMed
5. Böhme M, Müller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology. 1994;107:255-265. https://doi.org/10.1016/0016-5085(94)90084-1 - PubMed
6. Mizuta K, Kobayashi E, Uchida H, et al. Cyclosporine inhibits transport of bile acid in rats: comparison of bile acid composition between liver and bile. Transplant Proc. 1999;31:2755-2756. https://doi.org/10.1016/s0041-1345(99)00554-0 - PubMed
7. Morán D, González De Buitrago JM, Fernández E, Galán AI, Eugenia Muñoz M, Jiménez R. Inhibition of biliary glutathione secretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug. J Hepatol. 1998;29:68-77. https://doi.org/10.1016/s0168-8278(98)80180-3 - PubMed
8. Stacey NH, Kotecka B. Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology. 1988;95:780-786. https://doi.org/10.1016/s0016-5085(88)80028-3 - PubMed
9. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118:422-430. https://doi.org/10.1016/s0016-5085(00)70224-1 - PubMed
10. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18:16-22. https://doi.org/10.2133/dmpk.18.16 - PubMed
11. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact. 2004;150:179-187. https://doi.org/10.1016/j.cbi.2004.08.008 - PubMed
12. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x - PubMed
13. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001;276:9626-9630. https://doi.org/10.1074/jbc.M004968200 - PubMed
14. Shinji N, Akio U, Masami B, et al. The guidelines for the diagnosis and treatment of aplastic anaemia. Rinsho Ketsueki. 2006;47:27-46. https://doi.org/10.11406/rinketsu.47.27. (in Japanese). - PubMed
15. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476-485. https://doi.org/10.1016/j.gastro.2005.05.009 - PubMed
16. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730-1744. https://doi.org/10.1592/phco.26.12.1730 - PubMed
17. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:325-334. https://doi.org/10.1016/j.bbmt.2005.10.022 - PubMed
18. Templeton I, Peng C-C, Thummel K, Davis C, Kunze K, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010;88:499-505. https://doi.org/10.1038/clpt.2010.119 - PubMed
19. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: an evolution in effectiveness. Transplant Proc. 2000;32:45S-52S. https://doi.org/10.1016/s0041-1345(00)00863-0 - PubMed

Publication Types

• Case Reports